These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 17325657)

  • 21. [Use of levosimendan in acute heart failure and its effect on renal function].
    Moyano AP; Hidalgo RL; Grande DB; Morales SC
    Nefrologia; 2009; 29(6):616-7. PubMed ID: 19936016
    [No Abstract]   [Full Text] [Related]  

  • 22. Levosimendan: a review of its use in the management of acute decompensated heart failure.
    Innes CA; Wagstaff AJ
    Drugs; 2003; 63(23):2651-71. PubMed ID: 14636085
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Levosimendan and calcium sensitization of the contractile proteins in cardiac muscle: impact on heart failure.
    Kota B; Prasad AS; Economides C; Singh BN
    J Cardiovasc Pharmacol Ther; 2008 Dec; 13(4):269-78. PubMed ID: 19087950
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pimobendan. A review of its pharmacology and therapeutic potential in congestive heart failure.
    Fitton A; Brogden RN
    Drugs Aging; 1994 May; 4(5):417-41. PubMed ID: 8043944
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Calcium sensitising agents in heart failure.
    Mathew L; Katz SD
    Drugs Aging; 1998 Mar; 12(3):191-204. PubMed ID: 9534020
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of levosimendan on markers of kidney function in patients with acutely decompensated heart failure and renal impairment.
    Rafouli-Stergiou P; Parissis JT; Farmakis D; Bistola V; Frogoudaki A; Vasiliadis K; Ikonomidis I; Paraskevaidis I; Kremastinos D; Filippatos G; Lekakis J
    J Cardiovasc Med (Hagerstown); 2017 Oct; 18(10):771-773. PubMed ID: 25643197
    [No Abstract]   [Full Text] [Related]  

  • 27. Levosimendan.
    Figgitt DP; Gillies PS; Goa KL
    Drugs; 2001; 61(5):613-27; discussion 628-9. PubMed ID: 11368286
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Levosimendan in cardiac surgery: a unique drug for the treatment of perioperative left ventricular dysfunction or just another inodilator searching for a clinical application?
    Pagel PS
    Anesth Analg; 2007 Apr; 104(4):759-61. PubMed ID: 17377077
    [No Abstract]   [Full Text] [Related]  

  • 29. Ca2+ sensitizer superior to catecholamine during myocardial stunning?
    Meyer K; Klocke RC; Schipke JD; Gams E; Korbmacher B
    Eur J Cardiothorac Surg; 2008 Aug; 34(2):326-31. PubMed ID: 18539040
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The utility of levosimendan in the treatment of heart failure.
    Lehtonen L; Põder P
    Ann Med; 2007; 39(1):2-17. PubMed ID: 17364447
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [If the myofilaments become sensitive: Ca2+-sensitizer for the therapy of heart insufficiency].
    Schwinger RH; Brixius K
    Dtsch Med Wochenschr; 2005 Apr; 130(15):969-73. PubMed ID: 15812725
    [No Abstract]   [Full Text] [Related]  

  • 32. Pharmacologic treatment of heart failure due to ventricular dysfunction by myocardial stunning: potential role of levosimendan.
    García González MJ; Domínguez Rodríguez A
    Am J Cardiovasc Drugs; 2006; 6(2):69-75. PubMed ID: 16555860
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mechanism of action of Ca2+ sensitizers--update 2001.
    Endoh M
    Cardiovasc Drugs Ther; 2001 Sep; 15(5):397-403. PubMed ID: 11855658
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inodilators in the Management of Low Cardiac Output Syndrome After Pediatric Cardiac Surgery.
    Ferrer-Barba A; Gonzalez-Rivera I; Bautista-Hernandez V
    Curr Vasc Pharmacol; 2016; 14(1):48-57. PubMed ID: 26463985
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inotropic agents with calcium-sensitizing properties: clinical and hemodynamic effects of pimobendan.
    Kubo SH
    Coron Artery Dis; 1994 Feb; 5(2):119-26. PubMed ID: 8180743
    [No Abstract]   [Full Text] [Related]  

  • 36. Pharmacology of levosimendan: inotropic, vasodilatory and cardioprotective effects.
    Pathak A; Lebrin M; Vaccaro A; Senard JM; Despas F
    J Clin Pharm Ther; 2013 Oct; 38(5):341-9. PubMed ID: 23594161
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety of levosimendan and other calcium sensitizers.
    Lehtonen L; Mills-Owens P; Akkila J
    J Cardiovasc Pharmacol; 1995; 26 Suppl 1():S70-6. PubMed ID: 8907134
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Ca2+ sensitizers].
    Endoh M
    Tanpakushitsu Kakusan Koso; 2000 Apr; 45(6 Suppl):859-67. PubMed ID: 10771644
    [No Abstract]   [Full Text] [Related]  

  • 39. Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure.
    Parissis JT; Adamopoulos S; Antoniades C; Kostakis G; Rigas A; Kyrzopoulos S; Iliodromitis E; Kremastinos D
    Am J Cardiol; 2004 May; 93(10):1309-12. PubMed ID: 15135713
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evidence-based use of levosimendan in different clinical settings.
    De Luca L; Colucci WS; Nieminen MS; Massie BM; Gheorghiade M
    Eur Heart J; 2006 Aug; 27(16):1908-20. PubMed ID: 16682381
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.